Scholars Central

EditorialPublished 10 Dec 2015

New Frontiers in Vitiligo Treatment: The Low Dose Cytokines-Based Therapy

Authors: Torello Lotti

Medical Case Reports

Volume 2 · Issue 2 · Pages 18

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Skin depigmentation phenomena, caused by the loss of melanocytes, are the distinctive feature of vitiligo. The inner mechanisms of melanocyte loss are still unclear; however, an increasing number of basic and clinical observations highlighted the fundamental role of cellular immunity, chronic inflammatory phenomena and intercellular cross-talk breakdown in vitiligo pathogenesis. The modulation of inflammatory phenomena and immune response and the restoration of keratinocytes-melanocytes axis with specific low dose SKA interleukins, antibodies and basic fibroblast growth factor represent an innovative therapeutic approach for vitiligo treatment based on Low Dose Medicine paradigm. Keywords: Vitiligo; Low dose medicine; Inflammation; Sequential kinetic activation; Interleukin 4; Interleukin 10; Anti-interleukin-1 antibodies; Basicfibroblast growth factor

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Medical Case Reports.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalMedical Case Reports
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Torello Lotti”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels